Invertebrate models of neurologic disease: Insights into pathogenesis and therapy

Current Neurology and Neuroscience Reports

Volumn 3, Issue 5, 2003, Pages 442-448

  Thompson, Leslie Michels ^a   Marsh, J Lawrence ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONGO RED; CYSTAMINE; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; ENZYME INHIBITOR; GELDANAMYCIN; HISTONE DEACETYLASE INHIBITOR; PROTEIN INHIBITOR; QBP 1; TYROSINE 3 MONOOXYGENASE INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL MODEL; CAENORHABDITIS ELEGANS; DEGENERATIVE DISEASE; DROSOPHILA; INVERTEBRATE; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; REVIEW; TAUOPATHY; ANIMAL; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NERVOUS SYSTEM DISEASES; NEURODEGENERATIVE DISEASES;

EID: 0642336407     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-003-0028-7     Document Type: Review

References (61)

1. Rubin GM, Yandell MD, Wortman JR, et al.: Comparative genomics of the eukaryotes. Science 2000, 287:2204-2215.
2. Culetto E, Sattelle DB: A role for Caenorhabditis elegans in understanding the function and interactions of human disease genes. Hum Mol Genet 2000, 9:869-877.
3. Reiter LT, Potocki L, Chien S, et al.: A systematic analysis of human disease-associated gene sequences in Drosophila melanogaster. Genome Res 2001, 11:1114-1125.
4. Sonnhammer EL, Durbin R: Analysis of protein domain families in Caenorhabditis elegans. Genomics 1997, 46:200-216.
5. Brodsky MH, Nordstrom W, Tsang G, et al.: Drosophila p53 binds a damage response element at the reaper locus. Cell 2000, 101:103-113.
6. Ollmann M, Young LM, Di Como CJ, et al.: Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell 2000, 101:91-101.
7. Min KT, Beazer S: Preventing neurodegeneration in the Drosophila mutant bubblegum. Science 1999, 284:1985-1988.
8. Min KT, Benzer S: Spongecake and eggroll: two hereditary diseases in Drosophila resemble patterns of human brain degeneration. Curr Biol 1997, 7:885-888.
9. Finley KD, Edeen PT, Cumming RC, et al.: blue cheese mutations define a novel, conserved gene involved in progressive neural degeneration. J Neurosci 2003, 23:1254-1264.
10. Driscoll M, Gerstbrein B: Dying for a cause: invertebrate genetics takes on human neurodegeneration. Nat Rev Genet 2003, 4:181-194.
11. Raeber AJ, Muramoto T, Kornberg TB, Prusiner SB: Expression and targeting of Syrian hamster prion protein induced by heat shock in transgenic Drosophila melanogaster. Mech Dev 1995, 51:317-327.
12. Link CD: Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A 1995, 92:9368-9372.
13. Brand A, Perrimon N: Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 1993, 118:401-415.
14. Bonini NM, Fortini ME: Human neurodegenerative disease modeling using Drosophila. Annu Rev Neurosci 2003, in press.
15. Bates G, Harper P, Jones L: Huntington's Disease, edn 3. Oxford: Oxford University Press; 2002.
16. Ross CA: Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 2002, 35:819-822.
17. Zoghbi HY, Orr HT: Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000, 23:217-247.
18. Link CD: Transgenic invertebrate models of age-associated neurodegenerative diseases. Mech Ageing Dev 2001, 122:1639-1649.
19. Baumeister R, Ge L: The worm in us - Caenorhabditis elegans as a model of human disease. Trends Biotechnol 2002, 20:147-148.
20. Warrick JM, Paulson HL, Gray-Board GL, et al.: Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 1998, 93:939-949.
21. Jackson GR, Salecker I, Dong X, et al.: Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998, 21:633-642.
22. Peters MF, Nucifora FC Jr, Kushi J, et al.: Nuclear targeting of mutant Huntingtin increases toxicity. Mol Cell Neurosci 1999, 14:121-128.
23. Saudou F, Finkbeiner S, Devys D, Greenberg M: Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
24. Marsh JL, Walker H, Theisen H, et al.: Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Gen 2000, 9:13-25.
25. Kazemi-Esfarjani P, Benzer S: Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000, 5459:1837-1840.
26. Fernandez-Funez P, Nino-Rosales ML, Gouyon B, et al.: Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 2000, 408:101-106.
27. Takeyama K, Ito S, Yamamoto A, et al.: Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 2002, 35:855-864.
28. Faber PW, Alter JR, MacDonald ME, Hart AC: Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci U S A 1999, 96:179-184.
29. Parker JA, Connolly JB, Wellington C, et al.: Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc Natl Acad Sci U S A 2001, 98:13318-13323.
30. Haass C, Kahle PJ: Parkinson's pathology in a fly. Nature 2000, 404:341-343.
31. Feany MB, Bender WW: A Drosophila model of Parkinson's disease. Nature 2000, 404:394-398.
32. Lakso M, Vartiainen S, Moilanen AM, et al.: Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 2003, 86:165-172.
33. Jackson GR, Wiedau-Pazos M, Sang TK, et al.: Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002, 34:509-519.
34. Wittmann CW, Wszolek MF, Shulman JM, et al.: Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001, 293:711-714.
35. Kazemi-Esfarjani P, Benzer S: Suppression of polyglutamine toxicity by a Drosophila homolog of myeloid leukemia factor 1. Hum Mol Genet 2002, 11:2657-2672.
36. Faber PW, Voisine C, King DC, et al.: Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity. Proc Natl Acad Sci U S A 2002, 99:17131-17136.
37. Warrick JM, Chan HY, Gray-Board GL, et al.: Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 1999, 23:425-428.
38. Chan HY, Warrick JM, Gray-Board GL, et al.: Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy, and modulation of protein solubility in Drosophila. Hum Mol Genet 2000, 9:2811-2820.
39. Satyal SH, Schmidt E, Kitagawa K, et al.: Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci U S A 2000, 97:5750-5755.
40. Auluck PK, Chan HY, Trojanowski JQ, et al.: Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002, 295:865-868.
41. Cha JH: Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000, 2000:387-392.
42. Steffan JS, Bodai L, Pallos J, et al.: Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
43. Taylor JP, Taye AA, Campbell C, et al.: Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein. Genes Dev 2003, 17:1463-1468.
44. Chen HK Fernandez-Funez P, Acevedo SF, et al.: Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 2003, 113:457-468.
45. Yoshihara M, Ensminger AW, Littleton JT: Neurobiology and the Drosophila genome. Funct Integr Genomics 2001, 1:235-240.
46. Manev H, Dimitrijevic N, D44844zitoyeva S: Techniques: fruit flies as models for neuropharmacological research. Trends Pharmacol Sci 2003, 24:41-43.
47. Hughes RE, Lo RS, Davis C, et al.: Altered transcription in yeast expressing expanded polyglutamine. Proc Natl Acad Sci U S A 2001, 98:13201-13206.
48. McCampbell A, Taye AA, Whitty L, et al.: Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc Natl Acad Sci U S A 2001, 98:15179-15184.
49. Heemskerk J, Tobin AJ, Bain LJ: Teaching old drugs new tricks. Meeting of the Neurodegeneration Drug Screening Consortium, 7-8 April 2002, Washington, DC, USA. Trends Neurosci 2002, 25:494-496.
50. Apostol BL, Kazantsev A, Raffioni S, et al.: A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci U S A 2003, 100:5950-5955.
51. Kazantsev A, Walker H, Slepko N, et al.: A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat Genet 2002, 30:367-376.
52. Nagai Y, Fujikake N, Ohno K, et al.: Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. Hum Mol Genet 2003, 12:1253-1259.
53. Caldwell GA, Cao S, Sexton EG, et al.: Suppression of polyglutamine-induced protein aggregation in Caenorhabditis elegans by torsin proteins. Hum Mol Genet 2003, 12:307-319.
54. Heiser V, Engemann S, Brocker W, et al.: Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc Natl Acad Sci USA 2003, in press.
55. Dedeoglu A, Kubilus JK, Jeitner TM, et al.: Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 2003, in press.
56. Hockly E, Richon VM, Woodman B, et al.: Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2003, in press.
57. Karpuj MV, Becher MW, Springer JE, et al.: Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002, 8:143-149.
58. Sanchez I, Mahlke C, Yuan J: Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003, 421:373-379.
59. Auluck PK, Bonini NM: Pharmacological prevention of Parkinson disease in Drosophila. Nat Med 2002, 8:1185-1186.
60. Pendleton RG, Parvez F, Sayed M, Hillman R: Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. J Pharmacol Exp Ther 2002, 300:91-96.
61. Chan HY, Warrick JM, Andriola I, et al.: Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. Hum Mol Genet 2002, 11:2895-2904.